{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Daybreak","title":"India’s TB patients can finally celebrate the end of Johnson & Johnson’s monopoly disguised as charity","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/af10c7d9\"></iframe>","width":"100%","height":180,"duration":643,"description":"India’s patent office decided to reject pharma giant Johnson &Johnson’s appeal to extend the patent for a life-saving TB medicine called bedaquiline which is used to treat those with drug resistant infections. But for a long time before this, Johnson & Johnson was enjoying a monopoly in India. Generic manufacturers could not make this life-saving medicine. The Indian government too, at the time, had decided to protect the pharma giant.Not just that, Johnson & Johnson was also conveniently projecting itself as a charitable organisation through its health programmes.What does the Indian govt’s decision mean for TB patients in India now?","thumbnail_url":"https://img.transistorcdn.com/uPitovxKRYBGX6AWg9UrET6s3nAdkS-Ci9uZvsZj7vk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85ODhl/ZWM4NmEwZTcxZjZk/MDRlYjAzNTNkMjJi/ZGQ2YS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}